2012-10-04 07:52:25 - Recently published research from Global Markets Direct, "Cytheris SA - Product Pipeline Review - 2012", is now available at Fast Market Research

Global Market Direct's pharmaceuticals report, "Cytheris SA - Product Pipeline Review - 2012" provides data on the Cytheris SA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Cytheris SA's corporate website, SEC filings, investor presentations and featured press releases, both from Cytheris SA and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

* Cytheris SA - Brief Cytheris SA overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of Cytheris SA human therapeutic division.
* Overview of pipeline therapeutics

across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of Cytheris SA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the Cytheris SA's pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.


Full Report Details at
- www.fastmr.com/prod/468523_cytheris_sa_product_pipeline_review_2 ..


Reasons to buy

* Evaluate Cytheris SA's strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of Cytheris SA in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the Cytheris SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with Cytheris SA.
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of Cytheris SA and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Cytheris SA Snapshot
Cytheris SA Overview
Key Information
Key Facts
Cytheris SA - Research and Development Overview
Key Therapeutic Areas
Cytheris SA - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Cytheris SA - Pipeline Products Glance
Cytheris SA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cytheris SA - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cytheris SA - Drug Profiles
CY-T107 + Raltegravir + Maraviroc
Product Description
Mechanism of Action
R&D Progress
CYT-107
Product Description
Mechanism of Action
R&D Progress
CYT-107 + GenHevac + Entecavir
Product Description
Mechanism of Action
R&D Progress
CYT-107 + GenHevac + Tenofovir
Product Description
Mechanism of Action
R&D Progress
CYT-107 + Pegylated Interferon--Alpha + Ribavirin
Product Description
Mechanism of Action
R&D Progress
CYT-107 + Xeloda
Product Description
Mechanism of Action
R&D Progress
CYT-209
Product Description
Mechanism of Action
R&D Progress
CYT-99 007
Product Description
Mechanism of Action
R&D Progress
Cytheris SA - Pipeline Analysis
Cytheris SA - Pipeline Products by Therapeutic Class
Cytheris SA - Pipeline Products by Route of Administration
Cytheris SA - Pipeline Products By Mechanism of Action
Cytheris SA - Recent Pipeline Updates
Cytheris SA - Dormant Projects
Cytheris SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Cytheris SA, Recent Developments
Cytheris SA- Press Release
Jul 10, 2012: Cytheris Receives European Orphan Drug Designation For CYT107 For Treatment Of Progressive Multifocal Leukoencephalopathy
Mar 12, 2012: Cytheris Announces Results Of Phase II Study Indicating That Recombinant Interleukin-7 Expands CD4 T-cells In Gut Mucosa Of Chronically HIV Infected Immunological Non-responder Patients
Dec 08, 2009: Cytheris Announces Initiation Of CONVERT, A Phase I/IIa Study Of Recombinant Human Interleukin-7 (CYT107) In Combination With Antiviral Therapy And Vaccination For Treatment Of Chronic Hepatitis B Virus
Dec 08, 2009: Cytheris Announces Initiation Of CONVERT, A Phase I/IIa Study Of Recombinant Human Interleukin-7 (CYT107) In Combination With Antiviral Therapy And Vaccination For Treatment Of Chronic Hepatitis B Virus
Nov 23, 2009: Cytheris Announces Initiation Of NCI/NIH-Sponsored Phase I/IIa Clinical Study Of Tumor Vaccination And CYT107 (Interleukin-7 (IL-7)) In Patients With High Risk Pediatric Solid Tumors
Nov 25, 2009: Cytheris Announces Initiation Of NCI/NIH-Sponsored Phase I/IIa Clinical Study Of Tumor Vaccination And Interleukin-7 (IL-7) In Patients With High Risk Pediatric Solid Tumors
Oct 14, 2009: Cytheris Announces Initiation Of NIAID/NIH-Sponsored Phase I/IIa Clinical Trial Of CYT107 (Interleukin-7 (IL-7))

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468523&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.